Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 1, 2010, Pages 36-46

  Schweighardt, Becky ^a   Wrin, Terri ^a   Meiklejohn, Duncan A ^b   Spotts, Gerald ^c   Petropoulos, Christos J ^a   Nixon, Douglas F ^b   Hecht, Frederick M ^c  

^a MONOGRAM BIOSCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD8+ T cell responses; HIV immune escape; HIV 1 Gag gene; Neutralizing antibodies; Treatment interruption

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AZATHIOPRINE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; HLA ANTIGEN CLASS 1; LAMIVUDINE; NEUTRALIZING ANTIBODY; NEVIRAPINE; VIRUS GLYCOPROTEIN;

ADULT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG WITHDRAWAL; ENVELOPE GENE; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE ESCAPE MUTATION; IMMUNE RESPONSE; INFECTION CONTROL; LONGITUDINAL STUDY; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIREMIA; VIRUS GENE; VIRUS IMMUNITY; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; LONGITUDINAL STUDIES; MUTATION; NEUTRALIZATION TESTS; VIRAL LOAD; VIRUS REPLICATION; WITHHOLDING TREATMENT;

EID: 74049163820     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181c4b885     Document Type: Article

References (36)

1. + T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol. 2001;75: 6508-6516.
2. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 1999;5:518-525.
3. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol. 1999;73:797-800.
4. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999;340: 1683-1684.
5. Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999;104: R13-R18.
6. Binley JM, Trkola A, Ketas T, et al. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis. 2000;182: 945-949.
7. Lori F, Lewis MG, Xu J, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science. 2000;290: 1591-1593.
8. Ruiz L, Martinez-Picado J, Romeu J, et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS. 2000;14:397-403.
9. Yu XG, Addo MM, Rosenberg ES, et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol. 2002;76:8690-8701.
10. Oxenius A, Price DA, Gunthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A. 2002;99: 13747-13752.
11. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis. 2002;186:634-643. (Pubitemid 34925535)
12. El-Sadr WM, Grund B, Neuhaus J, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008;149:289-299.
13. Kaufmann DE, Lichterfeld M, Altfeld M, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med. 2004;1(2):e36.
14. Montefiori DC, Hill TS, Vo HT, et al. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol. 2001;75:10200-10207.
15. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-526.
16. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006;194:725-733.
17. Meiklejohn DA, Karlsson RK, Karlsson AC, et al. ELISPOT cell rescue. J Immunol Methods. 2004;288:135-147.
18. Kaufmann DE, Bailey PM, Sidney J, et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol. 2004;78:4463-4477.
19. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673-4680.
20. Richman DD, Wrin T, Little SJ, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100:4144-4149.
21. Schweighardt B, Liu Y, Huang W, et al. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr. 2007;46:1-11.
22. Liu Y, McNevin J, Zhao H, et al. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol. 2007;81:12179-12188.
23. Martinez-Picado J, Prado JG, Fry EE, et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol. 2006;80:3617-3623.
24. Peyerl FW, Bazick HS, Newberg MH, et al. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol. 2004;78:13901-13910.
25. Schneidewind A, Brockman MA, Sidney J, et al. Structural and functional constraints limit options for cytotoxic T-lymphocyte escape in the immunodominant HLA-B27-restricted epitope in human immunodeficiency virus type 1 capsid. J Virol. 2008;82:5594-5605.
26. Troyer RM, McNevin J, Liu Y, et al. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 2009;5:e1000365.
27. Daucher M, Price DA, Brenchley JM, et al. Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells. J Virol. 2008;82:4102-4114.
28. Appay V, Nixon DF, Donahoe SM, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000;192:63-75.
29. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107: 4781-4789.
30. Betts MR, Gray CM, Cox JH, et al. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. Expert Rev Vaccines. 2006;5:505-516.
31. Lichterfeld M, Kaufmann DE, Yu XG, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med. 2004;200:701-712.
32. Lichterfeld M, Yu XG, Waring MT, et al. HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha. Blood. 2004;104: 487-494.
33. Addo MM, Draenert R, Rathod A, et al. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE. 2007;2(3): e321.
34. D'Souza MP, Altfeld M. Measuring HIV-1-specific T cell immunity: how valid are current assays? J Infect Dis. 2008;197:337-339.
35. Yang OO. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes. AIDS. 2008;22:325-331.
36. Lieberman J. Tracking the killers: how should we measure CD8 T cells in HIV infection? AIDS. 2004;18:1489-1493.